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Background: Increasing evidence provides a clear association between rapid eye movement sleep behavior
disorders (RBD) and Parkinson’s disease (PD), but the clinical features that determine the co-morbidity of RBD and
PD are not yet fully understood.
Methods: We evaluated the characteristics of nocturnal disturbances and other motor and non-motor features
related to RBD in patients with PD and the impact of RBD on their quality of life. Probable RBD (pRBD) was
evaluated using the Japanese version of the RBD screening questionnaire (RBDSQ-J).
Results: A significantly higher frequency of pRBD was observed in PD patients than in the controls (RBDSQ-J≥ 5 or≥ 6:
29.0% vs. 8.6%; 17.2% vs. 2.2%, respectively). After excluding restless legs syndrome and snorers in the PD patients, the
pRBD group (RBDSQ-J≥5) showed higher scores compared with the non-pRBD group on the Parkinson’s disease sleep
scale-2 (PDSS-2) total and three-domain scores. Early morning dystonia was more frequent in the pRBD group. The
Parkinson’s Disease Questionnaire (PDQ-39) domain scores for cognition and emotional well-being were higher in the
patients with pRBD than in the patients without pRBD. There were no differences between these two groups with
respect to the clinical subtype, disease severity or motor function. When using a cut-off of RBDSQ-J = 6, a similar trend
was observed for the PDSS-2 and PDQ-39 scores. Patients with PD and pRBD had frequent sleep onset insomnia,
distressing dreams and hallucinations. The stepwise linear regression analysis showed that the PDSS-2 domain “motor
symptoms at night”, particularly the PDSS sub-item 6 “distressing dreams”, was the only predictor of RBDSQ-J in PD.
Conclusion: Our results indicate a significant impact of RBD co-morbidity on night-time disturbances and quality of life in
PD, particularly on cognition and emotional well-being. RBDSQ may be a useful tool for not only screening RBD in PD
patients but also predicting diffuse and complex clinical PD phenotypes associated with RBD, cognitive impairment and
hallucinations.
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Rapid eye movement (REM) sleep behavior disorder
(RBD) is characterized by the loss of normal muscle ato-
nia during REM sleep and dream-enacting behaviors
during REM sleep, and it often leads to injury of the pa-
tient or the bed partner [1]. RBD has been reported to
predominantly affect males over the age of 50, and it
correlates with neurodegenerative disease, particularly
alpha synucleinopathies, such as Parkinson’s disease
(PD), multiple system atrophy and dementia with Lewy
bodies [2]. Schenck and colleagues have reported that
3.7 ± 1.4 years after an initial diagnosis of idiopathic
RBD, 38% of patients developed a parkinsonian syn-
drome [3]. In a recent prospective study of idiopathic
RBD patients, the estimated 5-year risk of neurodegen-
erative disease was 17.7%, the 10-year risk was 40.6%
and the 12-year risk was 52.4% [4].
The frequency of RBD is reported to be up to 60% of
PD patients [5]. PD patients with RBD have been
reported to manifest a characteristic PD subtype that
comprises an akinetic-rigid (non-tremor) phenotype with
an increased frequency of falls, a poor response to dopa-
minergic medications, autonomic dysfunction and
impaired color vision [6-9]. The Braak staging system for
PD [10], which is based on the temporal sequence of
alpha synuclein pathology, shows that pathologic changes
begin in the medulla and olfactory bulb (stage 1) and as-
cend to the rostral regions (stage 2), including the subla-
terodorsal nucleus, magnocellular reticular formation
and peri-locus coeruleus structures, which are associated
with RBD [11]; the changes then reach the midbrain
(stage 3) and eventually the cortical structures (stages 4
and 5). This staging may help explain how RBD can pre-
cede parkinsonism and cognitive decline in PD; however,
whether RBD and PD co-morbidity results in more se-
vere or extensive brain involvement than PD alone
remains unknown, and whether differences exist between
these two groups (RBD and non-RBD groups) in disease
severity and motor score is still controversial [6,9,12-16].
Moreover, despite a number of studies that have evalu-
ated daytime motor and non-motor features of RBD in
PD, the characteristics of RBD-mediated nocturnal pro-
blems remain poorly studied in PD patients.
The current diagnostic criteria for RBD require poly-
somnography (PSG), which is used to demonstrate
REM sleep without atonia [17]. However, given the cost
and facilities required for PSG, questionnaires that ad-
equately screen for “probable RBD” are useful for clin-
ical studies [18]. We evaluated nocturnal disturbances and
motor and non-motor symptoms associated with the pres-
ence of pRBD in PD patients and the impact of RBD on
the quality of life (QOL). We used the self-administered
Parkinson’s disease sleep scale (PDSS)-2, which is a specific
questionnaire for PD-related sleep disturbances [19],and the Japanese version of the RBD screening ques-




This study is a cross-sectional, case-controlled study
conducted at the Department of Neurology, Dokkyo
Medical University between January 2011 and May 2011.
Subjects
The study sample consisted of a consecutive series of 93
PD patients (69.6 ± 8.9 years; 50 men and 43 women) who
were recruited from the validation study of the Japanese
version of the PDSS-2 [22]. Control subjects with no
neurological or psychiatric diseases (93 age- and gender-
matched subjects; 69.5 ± 10.2 years; 47 men and 46
women) were recruited from the medical staff and the
staff ’s friends and family. A diagnosis of PD was established
using the UK Parkinson’s Disease Society Brain Bank clin-
ical diagnostic criteria [23]. Patients with secondary parkin-
sonism due to medications or trauma were excluded.
Vascular parkinsonism or atypical Parkinson syndrome,
such as multiple system atrophy, progressive supranuclear
palsy, corticobasal degeneration or dementia with Lewy
bodies, were diagnosed using brain imaging and clinical
examinations, and patients with these diagnoses were
excluded. Individuals with dementia were diagnosed using
DSM-IV criteria and were excluded [24]. Bedridden
patients or patients who were unable to answer the ques-
tionnaire (even with the help of their caregiver or family)
were also excluded from this study.
Clinical assessment
The disease severity was rated using the Hoehn and Yahr
(HY) staging criteria [25]. Parts III and IV of the Unified
Parkinson’s Disease Rating Scale (UPDRS) were used to
evaluate the motor scores and complications of treat-
ment, respectively [26]. The UPDRS III score for each
cardinal motor feature was also evaluated as a propor-
tion of the total UPDRS part III score and included the
following: tremors, the total score for items 20 and 21
(seven items); rigidity, item 22 (five items); bradykinesia,
items 23–26 and 31 (nine items); gait/postural stability,
items 27–30 (four items) and bulbar abnormalities,
items 18 and 19 (two items) [6].
Clinical subtype
Motor phenotypes with tremor and non-tremor symp-
toms were compared as previously described [27]. The
tremor score was derived from the sum of UPDRS items
20 (tremor at rest) and 21 (action or postural tremor of
hands) divided by 7 (the number of single sub-items).
The non-tremor score was derived from the sum of
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(rigidity), 27 (arising from chair), 28 (posture), 29 (gait),
30 (postural stability) and 31 (body bradykinesia and
hypokinesia) divided by 12 (the number of single sub-
items). The tremor/non-tremor ratio was then calculated.
Axial-limb ratio
To compare the regional components of parkinsonism,
the UPDRS part III score was subdivided into axial and
limb divisions [6]. Axial signs were defined as UPDRS
items 18, 19, 22 and 27–30, and limb signs were defined
as items 20–26. The axial/limb ratio was calculated as
the summed axial scores/summed limb scores.
Questionnaires
Family members or care givers were allowed to help the
PD patients fill out their questionnaires. The Japanese
version of the RBD screening questionnaire (RBDSQ-J)
was used to determine probable RBD (pRBD) in this study
[28]. The RBDSQ is a recently developed self-rating instru-
ment, comprising the following 10 items on the most
prominent clinical features of RBD [21]: items 1 to 4, the
frequency and content of dreams and their relationship to
nocturnal movements and behavior; item 5, self-injuries
and injuries to the bed partner; item 6, four sub-items
that more specifically assess nocturnal motor behavior,
e.g., questions on nocturnal vocalization (6.1), sudden-limb
movements (6.2), complex movements (6.3) or bedding
items that fall down (6.4); items 7 and 8, nocturnal
awakenings; item 9, general disturbances of sleep; and
item 10, the presence of any neurological disorder.
Each item may be answered using either “yes” or
“no”. The maximum total score of the RBDSQ is 13
points. An RBDSQ score cut-off of 5.0 has been
considered useful for differentiating idiopathic RBD
patients from controls [21,28]. Nomura et al. [29] re-
cently reported that applying a cut-off of 6 in patients
with PD and RBD showed better discrimination from
those PD patients without RBD. However, PD patients
with RBD frequently exhibit a less severe form of ab-
normal behavior during REM sleep compared with
patients with idiopathic RBD [5,30]. We therefore
grouped patients using an RBDSQ-J cut-off of 5 or 6.
Next, we excluded patients with restless legs syn-
drome and snorers from the patients with pRBD and
those without pRBD. We then compared the clinical
profiles and demographic data of the patients with
both settings.
The QOL was evaluated using the Parkinson’s Disease
Questionnaire (PDQ-39) [31]. The PDQ-39 consists of
39 items that address 8 dimensions: mobility (10 items),
activities of daily living (ADL, 6 items), emotional well-
being (6 items), stigma (4 items), social support (3 items),
cognition (4 items), communication (3 items) and bodilydiscomfort (3 items). The scores for each dimension and
the summary index (SI), which is the sum of the eight
dimension scores, were calculated on a scale from 0
(perfect health as assessed by this measure) to 100
(worst health as assessed by this measure). The Beck
Depression Inventory (BDI)-II was used to evaluate de-
pressive symptoms [32].
The Japanese version of the PDSS-2 was used to
evaluate nocturnal disturbances [22]. The PDSS-2
consists of 15 individual items that measure nocturnal
disturbance [19]. The scores for each item assess the
frequency of symptoms and range from 0 (never) to 4
(very often). The total score ranges from 0 (symptom-
free) to 60 (highly symptomatic). The PDSS-2 was fur-
ther divided into three domain scores by summing
groups of 5 individual item scores (for a maximum
score of 20):“disturbed sleep” (items 1–3, 8 and 14);
“motor symptoms at night” (items 4–6, 12 and 13);
and “PD symptoms at night” (items 7, 9–11 and 15).
Snoring was defined as a snoring frequency of ≥ 2 days
per week (scores of 2 or higher for PDSS-2 item 15
(breathing problems)). The Pittsburgh sleep quality
index (PSQI) was used to evaluate the quality of sleep
[33]. The following seven component scores were also
estimated (range of subscale scores, 0–3): C1, sleep
quality; C2, sleep latency; C3, sleep duration; C4, ha-
bitual sleep efficiency; C5, sleep disturbances; C6, use
of sleeping medications; and C7, daytime dysfunction.
Daytime sleepiness was measured using the Japanese
version of the Epworth sleepiness scale (ESS) [34].
Restless legs syndrome (RLS) was diagnosed using
four essential criteria for RLS, as previously described
by the International Restless Legs Syndrome Study
Group [35]. The Parkinson fatigue scale (PFS) was
used to assess PD-mediated fatigue [36,37]. The levo-
dopa equivalent dose (LED) was calculated based on
findings reported in a systematic review on LED [38].
This study was performed in accordance with the
Declaration of Helsinki and was approved by the insti-
tutional review boards of Dokkyo Medical University.
Written, informed consent was obtained from all sub-
jects enrolled in this study.
Statistical analysis
The Mann–Whitney U test and unpaired t test were
used, as appropriate, to compare continuous vari-
ables, and the Chi-Squared and Fisher’s exact tests
were used to compare frequencies between groups.
Spearman rank correlation coefficients were used to
assess the correlation between RBDSQ-J and other
variables. Stepwise linear regression analyses, which
included age, gender, disease duration, UPDRS III,
the presence of motor complications, PSQI, ESS,
BDI-II, the presence of RLS, PFS, LED and PDSS-2
Table 1 The clinical characteristics of the controls and PD
patients
PD Controls p value
N (M/F) 93, (50/43) 93, (47/46) 0.66
Age (yrs) 69.7 ± 8.9 69.6 ± 10.2 0.94
Body mass index (kg/m2) 22.3 ± 2.8 22.9 ± 3.1 0.18
* RLS, n (%) 5 (5.5) 2 (2.2) 0.44
Snoring (at least 2 days/week), n (%) 13 (14.0) 1 (1.1) 0.0010
RBDSQ-J≥ 5, n (%) 27 (29.0) 8 (8.6) <0.001
RBDSQ-J≥ 6, n (%) 16 (17.2) 2 (2.2) <0.001
RBDSQ-J 3.3 ± 2.5 1.7 ± 1.7 <0.001
PSQI global score 5.4 ± 3.7 4.5 ± 3.2 0.068
PSQI component score
Sleep quality 1.0 ± 0.7 0.8 ± 0.6 0.024
Sleep latency 0.8 ± 1.0 1.0 ± 1.0 0.40
Sleep duration 0.8 ± 0.9 0.8 ± 0.9 0.62
Habitual sleep efficiency 0.5 ± 0.9 0.5 ± 0.8 0.67
Sleep disturbances 0.9 ± 0.6 0.8 ± 0.6 0.47
Use of sleeping medication 0.7 ± 1.2 0.6 ± 1.1 0.48
Daytime dysfunction 0.7 ± 0.9 0.2 ± 0.4 <0.001
ESS 6.6 ± 4.5 4.7 ± 3.0 <0.001
PDSS-2 total score 15.0 ± 9.7 9.1 ± 6.6 <0.001
PDSS-2 domain score
Disturbed sleep 7.6 ± 3.5 5.6 ± 3.4 <0.001
Motor symptoms at night 3.9 ± 4.1 1.8 ± 2.5 <0.001
PD symptoms at night 3.5 ± 3.6 1.6 ± 2.1 <0.001
PDQ-39 summary index 29.1 ± 21.7 NA
PDQ-39 domain score
Mobility 40.7 ± 33.9 NA
ADL 33.0 ± 29.4 NA
Emotional well-being 29.2 ± 25.8 NA
Stigma 22.1 ± 22.4 NA
Social support 12.0 ± 20.9 NA
Cognition 23.6 ± 21.2 NA
Communication 17.3 ± 20.8 NA
Bodily discomfort 25.1 ± 24.8 NA
BDI-II 13.3 ± 9.3 8.5 ± 6.8 <0.001
PFS 2.8 ± 1.1 1.7 ± 0.8 <0.001
Levodopa (mg/day) 304.8 ± 135.5 NA
LED (mg/day) 385.1 ± 315.0 NA
PD, Parkinson’s disease; RLS, restless legs syndrome; RBDSQ-J, Japanese
version of the REM sleep behavior disorder screening questionnaire; PSQI,
Pittsburgh Sleep Quality Index; ESS, Epworth Sleepiness Scale; PDSS-2,
Parkinson’s Disease Sleep Scale-2; PDQ-39, Parkinson’s Disease Questionnaire;
BDI-II, Beck Depression Inventory-II; PFS, Parkinson Fatigue Scale; LED,
Levodopa equivalent dose; NA, not applicable. *Data are missing for 4 controls
and 2 PD patients.
The data are presented as the n (%) or the means ± SD. Statistically significant
values (P < 0.05) are shown in bold.
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minants of the RBDSQ-J score. Significant differences
were two-tailed, with P < 0.05. A commercially avail-
able software package (IBM SPSS Statistics 19.0,
Tokyo, Japan) was used for the statistical analyses.
Results
The mean disease duration in the PD patients was 6.8 ±
6.1 years, and the mean HY stage was 2.6 ± 0.8. The
UPDRS III and UPDRS IV scores were 23.0 ± 13.9 and
1.8 ± 2.3, respectively. Motor complications were observed
in 35 patients (37.6%). Wearing-off phenomenon, early
morning dystonia and dyskinesia were present in 31
(33.3%), 7 (7.5%) and 18 (19.4%) patients, respectively.
Eight patients were drug naïve, 11 and 16 patients were
undergoing dopamine agonist and levodopa monother-
apies, respectively, and 58 patients were being treated with
a combination of levodopa and a dopamine agonist. The
clinical profiles of the PD patients and controls are shown
in Table 1. The PD patients showed a significantly higher
RBDSQ-J score than the controls. The PD patients also
exhibited a significant increase in the frequency of pRBD
compared with the controls (RBDSQ-J ≥ 5 or ≥ 6: 29.0% vs.
8.6%; 17.2% vs. 2.2%, respectively). The PSQI global score
showed a tendency to be higher in the PD patients than in
the controls. The ESS, BDI-II and PFS scores were signifi-
cantly different in the PD patients compared with the con-
trols, and the mean PDSS-2 total and domain scores in the
PD patients were higher than in the controls.
Table 2 shows the clinical characteristics of PD patients
with pRBD and those without pRBD after the exclusion of
RLS and snorers (defined using RBDSQ-J ≥ 5). The pRBD
group showed a higher rate of early morning dystonia and
higher scores of UPDRS IV and PDSS-2 total scores than
the non-pRBD group. The PDQ-39 domain scores for cog-
nition and emotional well-being were higher in the patients
with pRBD than in those without. In patients with and
without pRBD, the use of entacapone, selegiline, trihexy-
phenidyl, atypical neuroleptics, antiepileptics and antide-
pressants, including selective serotonin reuptake inhibitors,
tricyclics and tetracyclics, did not differ.
With respect to the PDSS-2 domain scores and sub-
items, patients with both PD and pRBD showed frequent
sleep onset insomnia (item 2), distressing dreams (item 6)
and distressing hallucinations (item 7) (Table 3). There
were no differences in the clinical subtypes, such as the
tremor/non-tremor ratio, axial/limb ratio and the UPDRS
III proportional scores, although the tremor score tended
to be higher in the pRBD group (Table 4).
When using a cut-off of RBDSQ-J ≥ 6, the frequency of
pRBD was 13.0% (after the exclusion of RLS and snorers;
10/77). No significant differences between these groups
were found with respect to age, body-mass index, disease
duration, HY stage, UPDRS III or IV, PSQI, ESS, BDI-II,







n; (M/F) 18; (9/9) 59; (31/28) 0.85
Age (yrs) 71.4 ± 5.0 68.3 ± 9.8 0.34
Body mass index (kg/m2) 22.8 ± 2.4 22.3 ± 2.8 0.72
Disease duration (yrs) 7.8 ± 5.5 6.4 ± 6.1 0.20
Hoehn and Yahr stage 2.7 ± 0.9 2.5 ± 0.8 0.49
UPDRS III 24.5 ± 12.0 19.9 ± 13.0 0.16
UPDRS IV 2.4 ± 2.4 1.6 ± 2.3 0.037
Motor complications, n (%) 8 (44.4) 19 (32.2) 0.34
Wearing-off, n (%) 5 (27.8) 18 (30.5) 1.0
Early morning dystonia, n (%) 4 (22.2) 0 (0.0) 0.0023
Dyskinesia, n (%) 5 (27.8) 10 (16.9) 0.32
PSQI global score 5.6 ± 4.0 5.1 ± 3.4 0.76
PSQI component score
Sleep quality 1.1 ± 0.8 0.9 ± 0.6 0.38
Sleep latency 0.9 ± 1.1 0.8 ± 0.9 0.54
Sleep duration 0.5 ± 0.8 0.9 ± 0.9 0.05
Habitual sleep efficiency 0.4 ± 0.7 0.5 ± 0.9 0.87
Sleep disturbances 0.8 ± 0.6 0.8 ± 0.6 0.83
Use of sleeping medication 0.9 ± 1.3 0.6 ± 1.1 0.14
Daytime dysfunction 0.8 ± 1.0 0.6 ± 0.8 0.39
ESS 7.3 ± 4.7 6.2 ± 4.5 0.34
PDSS-2 total score 16.1 ± 7.4 12.1 ± 7.9 0.044
PDQ-39 summary index 31.2 ± 24.4 23.8 ± 19.2 0.25
PDQ-39 domain score
Mobility 38.2 ± 35.8 33.9 ± 31.3 0.69
ADL 36.1 ± 33.4 27.4 ± 27.2 0.39
Emotional well-being 37.0 ± 27.2 22.4 ± 21.9 0.029
Stigma 22.2 ± 19.1 19.1 ± 21.9 0.22
Social support 12.0 ± 22.4 8.8 ± 16.6 0.44
Cognition 31.6 ± 21.1 17.5 ± 18.9 0.0038
Communication 19.4 ± 22.0 13.7 ± 18.2 0.27
Bodily discomfort 28.2 ± 25.4 21.5 ± 24.0 0.33
BDI-II 14.2 ± 9.1 11.6 ± 9.2 0.22
PFS 2.7 ± 1.1 2.7 ± 1.1 0.78
Levodopa (mg/day) 270.8 ± 135.6 315.7 ± 154.0 0.44
LED (mg/day) 312.9 ± 234.7 372.5 ± 338.0 0.87
PD, Parkinson’s disease; pRBD, probable REM sleep behavior disorder; UPDRS,
Unified Parkinson’s Disease Rating Scale; RLS, restless legs syndrome; RBDSQ-J,
Japanese version of the RBD screening questionnaire; PSQI, Pittsburgh Sleep
Quality Index; ESS, Epworth Sleepiness Scale; PDSS-2, Parkinson’s Disease Sleep
Scale-2; PDQ-39, Parkinson's Disease Questionnaire; BDI-II, Beck Depression
Inventory-II; PFS, Parkinson Fatigue Scale; LED, Levodopa equivalent dose. The data
are presented as the n (%) or the means ± SD. Statistically significant values
(P < 0.05) are shown in bold. Patients with RLS and snorers were excluded.
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(17.4 ± 8.4 vs. 12.4 ± 7.7, p = 0.073), and early morning
dystonia (20.0% vs. 0.0%, p = 0.073) tended be more
frequent in the pRBD group than the non-pRBD group.
The PDSS-2 domain “motor symptoms at night” (5.4 ± 3.9
vs. 2.9 ± 3.3, p = 0.039), item 6 (1.6 ± 1.3 vs. 0.5 ± 0.9,
p < 0.001) and item 7 (0.8 ± 1.0 vs. 0.2 ± 0.7, p = 0.0034)
were higher in the pRBD group than in the non-pRBD
group. Additionally, muscle cramps in the arms or legs
(item 11) (1.1 ± 0.9 vs. 0.6 ± 1.0, p = 0.043) were more fre-
quent in the pRBD group. The PDQ-39 emotional well-
being, cognition, stigma and communication domains
were significantly impaired in the pRBD group compared
with the non-pRBD group. There were no differences in
the clinical subtypes between these two groups.
Among the 77 PD patients without RLS and who were
not snorers, the RBDSQ-J score was significantly corre-
lated with the UPDRS IV (rs = 0.28, p = 0.013), PDSS-2
total (rs = 0.35, p = 0.0016) and all-domains scores (“dis-
turbed sleep”, rs = 0.33, p = 0.0033; “motor symptoms at
night”, rs = 0.30, p = 0.0072 and “PD symptoms at
night”, rs = 0.24, p = 0.035), PDQ-39 emotional well-being
(rs = 0.29, p = 0.011), cognition (rs = 0.46, p < 0.001) and
bodily discomfort (rs = 0.27, p = 0.022) and BDI-II score
(rs = 0.24, p = 0.035). There were significant correlations
with most of the PDSS sub-items except for items 1, 3, 8
and 13. There were no correlations between the RBDSQ-J
score and the UPDRS III score, disease duration, HY stage,
PSQI, ESS, PFS, LED or any clinical subtypes, such as the
tremor/non-tremor score and axial/limb ratio.
Stepwise linear regression analyses, which included
age, gender, disease duration, UPDRS III and IV, PSQI,
ESS, BDI-II, the presence of RLS, PFS, LED and PDSS-2
domain scores, revealed that the PDSS-2 domain “motor
symptoms at night” was the only predictor for RBDSQ-J
in PD (R2 = 0.078, p = 0.016). Next, to determine which
sub-item of the PDSS-2 domain “motor symptoms at
night” contributed to RBDSQ-J, we performed a second
stepwise linear regression analysis including age, gender,
disease duration, UPDRS III, presence of motor compli-
cations, BDI-II, PSQIG, ESS, PDSS sub-items of motor
symptoms at night (items 4, 5, 6, 12 and 13), PFS and
LED. The results showed that PDSS-2 item 6 “distres-
sing dreams” was the significant contributing factor to
RBDSQ-J (R2 = 0.078, p = 0.016).
Discussion
In this questionnaire-based study, we found a signifi-
cantly increased frequency of pRBD in PD patients com-
pared with a control population. The frequency of RBD
in our study is comparable with that observed in previ-
ous studies. In 469 non-demented Japanese PD patients,
the pRBD comorbidity was noted in 31.6% of the indivi-
duals (defined using RBDSQ-J ≥ 5) [39].
Table 3 PDSS-2 domain scores and sub-items in PD patients with and without pRBD
PDSS-2 Item pRBD (RBDSQ-J ≥ 5) Non-pRBD (RBDSQ-J < 5) p value
Disturbed sleep 8.3 ± 3.0 6.7 ± 3.3 0.066
Poor sleep quality 1 1.3 ± 1.4 1.0 ± 1.3 0.35
Difficulty falling asleep 2 1.7 ± 1.5 0.8 ± 1.0 0.013
Difficulty staying asleep 3 2.1 ± 1.3 1.8 ± 1.3 0.35
Tired/sleepy in the morning 14 0.9 ± 1.1 0.7 ± 0.9 0.62
Get up to pass urine 8 2.3 ± 1.2 2.4 ± 1.4 0.69
Motor symptoms at night 4.7 ± 3.6 2.8 ± 3.3 0.036
Restlessness of arms or legs 4 1.2 ± 1.1 0.8 ± 1.1 0.083
Urge to move arms or legs 5 0.8 ± 1.0 0.4 ± 0.8 0.084
Distressing dreams 6 1.3 ± 1.1 0.4 ± 0.8 <0.001
Painful posturing in morning 12 0.3 ± 0.7 0.4 ± 1.0 0.86
Tremor on waking 13 0.9 ± 1.4 0.7 ± 1.1 0.84
PD symptoms at night 3.1 ± 2.9 2.5 ± 3.0 0.31
Distressing hallucinations 7 0.6 ± 0.9 0.2 ± 0.7 0.0074
Uncomfortable and immobile 9 0.8 ± 1.0 0.7 ± 0.9 0.58
Pain in arms or legs 10 0.6 ± 0.8 0.7 ± 1.0 0.88
Muscle cramps in arms or legs 11 0.7 ± 0.8 0.6 ± 1.0 0.47
Breathing problems/snoring 15 0.4 ± 0.5 0.3 ± 0.5 0.60
PD, Parkinson’s disease; pRBD; probable REM sleep behavior disorder; PDSS-2, Parkinson’s Disease Sleep Scale-2. The data are presented as the n (%) or the means ± SD.
Statistically significant values (P < 0.05) are shown in bold. Patients with RLS and snorers were excluded.
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revealed similar clinical characteristics in the PD
patients. The original study of the RBDSQ showed that a
cut-off of 5 was useful for differentiating idiopathic RBD
patients from healthy subjects, showing a sensitivity of
96% and a specificity of 56% [21]. Similarly, in ourTable 4 Comparison of motor features in PD patients






Tremor score 0.4 ± 0.4 0.2 ± 0.3 0.062
Non-tremor score 1.0 ± 0.5 1.0 ± 0.6 0.73
Tremor/non-tremor score 0.5 ± 0.4 0.4 ± 0.6 0.079
Bulbar (% of total UPDRS III) 10.3 ± 6.3 10.8 ± 10.2 0.66
Tremor (% of total UPDRS III) 12.3 ± 9.4 9.6 ± 13.8 0.087
Rigidity (% of total UPDRS III) 22.8 ± 12.5 21.6 ± 14.8 0.54
Bradykinesia (% of total
UPDRS III)
40.4 ± 11.4 40.2 ± 15.5 0.71
Gait posture abnormality
(% of total UPDRS III)
14.2 ± 9.9 17.8 ± 13.3 0.35
Axial score 11.0 ± 5.6 10.3 ± 6.2 0.65
Limb score 16.2 ± 7.7 13.8 ± 9.7 0.19
Axial/limb ratio 0.7 ± 0.2 0.9 ± 0.5 0.20
PD, Parkinson’s disease; pRBD; probable REM sleep behavior disorder; UPDRS,
Unified Parkinson’s Disease Rating Scale. Patients with RLS and snorers
were excluded.previous validation study of the RBDSQ, an RBDSQ-J
cut-off of 5 was useful for differentiating Japanese idio-
pathic RBD patients from healthy subjects, with a sensi-
tivity of 88.5% and specificity of 96.9% [28]. Recently,
Nomura et al. [29] reported upon the usefulness of the
RBDSQ-J in Japanese PD patients. In that study, a cut-
off point of 6 yielded a sensitivity of 84.2% and a specifi-
city of 96.2%. This finding is in contrast with that of a
study assessing the sensitivity of clinical interviews (min-
imal diagnostic criteria of ICSD, revised) for diagnosing
PSG-confirmed RBD in PD patients and controls, which
revealed that in PD patients, a low sensitivity (33%) and
high specificity (90%) was observed whereas in controls,
an excellent sensitivity and specificity were noted (sensi-
tivity, 100%; specificity, 99.6%). The authors suggested
that these findings were due to common observations of
the mild form of RBD and unawareness of sleep pro-
blems and other sleep-related disturbances in patients
with PD [40]. The RBDSQ is, therefore, thought to have
superior sensitivity for detecting RBD, even in PD
patients. In the original version of the RBDSQ, comorbid
neurologic diseases such as PD were included in item
10. Patients with PD and RBD frequently exhibit a less
severe form of abnormal behavior during REM sleep
compared with individuals with idiopathic RBD [5,30].
Thus, we believe that applying a cut-off score of 5, which
can increase the sensitivity for detecting pRBD, may be
suitable for PD patients, and thereafter, PSG may be
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considered suitable for PSG examination.
There were no significant differences in the gender
ratio, disease duration, disease severity, UPDRS III
scores or PFS scores between the pRBD and non-
pRBD groups. Furthermore, the axial-limb ratio was
similar between the groups, a finding similar to that
of Postuma et al. [6]; however, they reported that
patients with PD who had a symmetric onset showed
increased RBD comorbidity and an increased percent-
age of tonic REM sleep compared with those showing
an asymmetric onset [41]. Several, but not all [6,9,15],
studies [13,14,16,42] have reported that patients with
RBD and PD manifest with non-tremor-dominant
type PD rather than tremor-dominant type PD. This
finding may imply a more extensive brain involve-
ment in those PD patients with RBD than in those
without because in non-tremor-dominant type PD,
patients show a more rapid motor deterioration whereas
tremor-dominant cases show a benign disease course [43].
Moreover, compared with the tremor-dominant PD
type, the akinetic-rigid type (non-tremor-dominant
type) showed severe neuronal loss in the medial and
lateral substantia nigra and locus coeruleus [44]. In
contrast, we found that disease duration, motor scores
and levodopa treatment did not differ between the two
PD groups, and we did not find a specific motor
subtype that correlated with pRBD, although there
was a trend towards a higher tremor score in the
pRBD group compared with the non-pRBD group.
Similarly, a study of 457 PD patients with sleep dis-
turbances did not find a characteristic clinical sub-
type for PD with RBD but did report a higher disease
severity and longer disease duration in PD patients
with RBD than those without [13]. Because most of
our patients were medicated, we cannot exclude that
a tremor-dominant type may transition into a non-
tremor-dominant type over time and with increased
age [45]. In early PD (disease duration of up to
5 years and HY stage of between 1 and 2.5), the RBD
co-morbidity (confirmed by clinical history during the
preceding 6 months and a cut-off score > 4 on the
RBDSQ) was high (55%); however, no differences in
the clinical subtype and disease severity have been
reported recently [42].
Our study demonstrated that the scores for the PDQ-39
cognition and emotional well-being dimensions were
higher in patients with pRBD than in those without pRBD.
Patients with idiopathic RBD have no cognitive or motor
complaints, but they frequently develop characteristic
motor and cognitive symptoms, such as impairment of
visuospatial abilities and deficits in verbal memory, atten-
tion and executive function, which are also observed in
patients with PD, PD with dementia, MCI and DLB [46].Several risk factors associated with dementia in PD, such
as the akinetic-rigid type, hallucinations, longer disease
duration and male gender, correlate with RBD in PD [46].
In our study, hallucinations also correlated significantly
with PD-RBD.
The negative impact of RBD on the QOL has been pre-
viously reported [7]. In that report, no changes were
found in the PDQ-39 score, but lower QOL scores were
noted (these scores were measured using the 36-item
short form health survey on emotional and mental func-
tioning) in PD patients with RBD, suggesting that
RBD in PD may affect the QOL in a non-disease-
specific manner. In contrast, in our study, similar compo-
nents of the QOL were affected in the PDQ-39, the
disease-specific QOL questionnaire for PD. Because the
pRBD group showed higher PDSS scores and PDQ-39
cognition dimensions than the group without pRBD,
impaired sleep may play a role in cognitive dimensions in
this study.
We found that PD patients with pRBD showed sig-
nificantly higher PDSS-2 scores related to sleep onset
insomnia, nocturnal hallucinations and vivid dreams
but that the ESS and PSQI scores were similar between
the groups. The impairment of REM sleep has been
attributed to the occurrence of visual hallucinations and
delusions in PD [47]. RBD is a possible predictor for the
development of cognitive impairment and visual halluci-
nations in PD, and RBD, hallucinations and cognitive im-
pairment may progress together with motor impairment
[48,49]. Because LED and disease severity were not dif-
ferent between the pRBD and non-pRBD groups, these
nocturnal dysfunctions may be related to impairments in
non-dopaminergic systems.
The limitations of our study include the absence of
PSG examinations, which may have resulted in an
underestimation of the frequency of RBD because the
frequency of RBD, diagnosed using clinical history alone,
ranges from 15% to 46% whereas the frequency of PSG-
confirmed RBD varies from 46% to 58% in PD patients
[5]. In addition, the absence of any significant difference
in several clinical characteristics and sleep parameters in
this study between the PD patients and controls and be-
tween the pRBD and non-pRBD groups may be due to
insufficient statistical power.
Conclusions
In conclusion, our results suggest a significant impact of
RBD co-morbidity on night time disturbances (as assessed
by PDSS-2) and the QOL, especially cognition and emo-
tional well-being, in PD. The RBDSQ, which addresses the
most prominent clinical features of RBD, may be a useful
tool for not only screening RBD in PD but also predicting
diffuse and complex clinical PD phenotypes associated
with RBD, cognitive impairment and hallucination.
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